Avidity Biosciences develops targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates platform. The company is focused on addressing unmet patient needs across various therapeutic areas.

Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 28, 2024 3:42 PM	763fbf76
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 28, 2024 3:42 PM	3a93a813
crunchbase trigger	general	Nov 18, 2024 2:12 PM	8866ba37
crunchbase profile	general	Nov 18, 2024 8:23 PM	15f0f59c
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 28, 2024 3:42 PM	1afcdda9
news basic	general	Sep 28, 2024 3:42 PM	0f76cd1b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AVIDITYBIOSCIENCES

Avidity Biosciences

Last Close

43.65

21/11 21:00

Market Cap

4.07B

Beta: -

Volume Today

750.46K

Avg: -